‘‘Effect of KarXT on Negative Symptoms in the Full Sample and Subgroup With Prominent Negative Symptoms
• In the full sample, KarXT (n=314) was associated with a significantly greater improvement from baseline to week 5
in PANSS Marder negative factor score compared with placebo (n=326) (least squares mean [LSM] difference=-1.97,
standard error [SE]=0.40, P<0.0001; Cohen’s d=0.42; Figure 2A)
• A total of 64 participants (10%) met criteria for having prominent negative symptoms at baseline. In this subgroup,
KarXT (n=29) was associated with a significantly greater reduction from baseline to week 5 in PANSS Marder negative
factor score compared with placebo (n=35) (LSM difference=-4.71, SE=1.16, P<0.0001; Cohen’s d=1.18) (Figure 2B)’’
3 Likes
So karxt is good for negative symptoms?
1 Like
Apparently yes. But until there is clinical evidence it cannot be confirmed. Everything seems to indicate that it will be much more tolerable than current antipsychotics.
4 Likes
Wooohooo good news
2 Likes
I swear I can’t wait to get that medicine in my hands.
3 Likes
Its suppose to be approved in September I wonder how long after approval until its on the market? Im in the US and planning on taking it right away
1 Like
It would be nice to have a psych med that actually lives up to the hype.
3 Likes
The United States has excellent logistics. In 2 or 3 months it would be supplying the local US market. At least that’s what my psychologist told me.
2 Likes
This topic was automatically closed 90 days after the last reply. New replies are no longer allowed.